Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2024-07-12 00:00:00 ET · period of report 2024-07-11 · accession 0001933414-24-000035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-07-12 | 2024-07-11+ | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $0.8416 | +11.4K | 102.9K | +12% | +$9,566 |
| DM | 2024-07-12 | 2024-07-11+ | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $0.00 | -11.4K | 30.1K | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-11 | M | A | 5,017 | $0.54 | 96,524 | D | — | — | (F1) This balance includes 1,778 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. |
| 2 | Common | Common Stock | 2024-07-12 | M | A | 6,349 | $1.08 | 102,873 | D | — | — | |
| 3 | Derivative | Stock Option | 2024-07-12 | M | D | 6,349 | $0.00 | 184,008 | D | $1.08 · — to 2032-07-11 | 6,349 Common Stock | (F4) Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. (F5) The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. |
| 4 | Derivative | Stock Option | 2024-07-11 | M | D | 5,017 | $0.00 | 30,104 | D | $0.54 · — to 2031-03-11 | 5,017 Common Stock | (F2) Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. (F3) The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. |